Eye on Pharma: Teva, Formycon, Celltrion Biosimilar Updates in Global Markets

January 26, 2025

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory announcements regarding new biosimilar products in Europe and Canada.

No Disease Activity Changes After Children With IBD Switched to Infliximab Biosimilar

January 25, 2025

The Top 5 Biosimilar Articles for the Week of January 20

January 24, 2025

Biosimilar Teriparatide Matches Forteo in Safety and Fracture Risk

January 23, 2025

Cost-Benefits, Efficacy of Biosimilar Ranibizumab vs Aflibercept for nAMD in Japan

January 22, 2025

The Top 5 Biosimilar Articles for the Week of August 5

August 9th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of August 5, 2024.

SB15 Biosimilar Demonstrates High Similarity to Reference Product Aflibercept

August 8th 2024

By Cameron Santoro

Article

In a comprehensive analysis, the biosimilar SB15 exhibited high similarity to reference aflibercept in terms of physicochemical and biological properties.

Manitoba Adopts Biosimilar Switching Policy

August 7th 2024

By Skylar Jeremias

Article

Manitoba’s new policy means that all 10 Canadian provinces now have an initiative to boost biosimilar adoption and savings by transitioning patients on reference agents to biosimilar options.

Eye on Pharma: Ustekinumab Updates; Ranibizumab Trial; Julie Reed PBM Piece

August 6th 2024

By Skylar Jeremias

Article

Several companies receive good news regarding their ustekinumab biosimilars; Lupin Limited completes a phase 3 trial for a ranibizumab candidate; Julie Reed, MS, executive director of the Biosimilars Forum weighs in on pharmacy benefit managers and biosimilar access.

Indian Providers Boast Interchangeability for Insulin Biosimilars Despite Debates in the US

August 5th 2024

By Skylar Jeremias

Article

The introduction of biosimilar insulins, particularly insulin glargine, is crucial for improving insulin accessibility and adherence among patients with diabetes in India, according to a study evaluating expert opinions from Indian doctors.

Biosimilars Policy Roundup for July 2024—Podcast Edition

August 4th 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, we review all the big biosimilar policy news from July, including discussions regarding biosimilar policies, in both the US and abroad, as well as 3 highly anticipated FDA approvals.

Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline

August 3rd 2024

By Skylar Jeremias

Article

Products in line to face biosimilar competition are projected to increase their list prices in advance, according to Vizient’s Pharmacy Market Outlook Report for Summer 2024.

The Top 5 Biosimilar Articles for the Week of July 29

August 2nd 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of July 29, 2024.

Biosimilars Policy Roundup: July 2024

August 1st 2024

By Skylar Jeremias

Article

July brought a lot of discussion regarding biosimilar policies, in both the US and abroad, as well as 3 highly anticipated FDA approvals.

Learning the Lingo of Biologics and Biosimilars Is Critical

July 31st 2024

By Jeannette Y. Wick, RPh, MBA, FASCP

Article

The number of FDA-approved biologics has exploded, and biosimilars are making their mark.